ak 2123 has been researched along with Fibrosarcoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, S; Mallia, MB; Mathur, A; Pillai, MR; Sarma, HD | 1 |
| Kagiya, TV; Nair, CK; Rajagopalan, R | 1 |
| Banerjee, S; Chakraborty, S; Das, T; Kagiya, VT; Mukherjee, A; Nair, CK; Samuel, G; Sarma, HD; Venkatesh, M | 1 |
3 other study(ies) available for ak 2123 and Fibrosarcoma
| Article | Year |
|---|---|
Preparation and evaluation of a ⁹⁹mTcN-PNP complex of sanazole analogue for detecting tumor hypoxia.
Topics: Animals; Cell Hypoxia; Fibrosarcoma; Mice; Organotechnetium Compounds; Radionuclide Imaging; Radiopharmaceuticals; Triazoles | 2013 |
Radiosensitizer sanazole (AK-2123) enhances gamma-radiation-induced apoptosis in murine fibrosarcoma.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Cell Nucleus; DNA Fragmentation; Fibrosarcoma; Gamma Rays; Genome; Male; Mice; Neoplasm Transplantation; Neoplasms, Radiation-Induced; Nucleosomes; Radiation-Sensitizing Agents; Sarcoma, Experimental; Time Factors; Triazoles | 2003 |
Preparation and preliminary biological evaluation of a 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia.
Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Fibrosarcoma; Hypoxia; Lutetium; Mice; Neoplasms; Radioisotopes; Radiopharmaceuticals; Tissue Distribution; Triazoles | 2004 |